Supplementary Material

Burden of moderate to severe atopic dermatitis in adults from France, Italy and the UK: patient-reported outcomes and treatment patterns

C. Elise Kleyn\textsuperscript{a}, Sébastien Barbarot\textsuperscript{b}, Catherine Reed\textsuperscript{d}, Serena Losi\textsuperscript{c}, Lill-Brith von Arx\textsuperscript{c}, Camille Robert\textsuperscript{c}, Peter Anderson\textsuperscript{d}, Susanne Grond\textsuperscript{c}, Antonio Costanzo\textsuperscript{e,f}

\textsuperscript{a}Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester National Institute for Health Research Biomedical Research Centre, The University of Manchester, Manchester, UK

\textsuperscript{b}Centre Hospitalier Universitaire de Nantes, Service de Dermatologie, Nantes, France

\textsuperscript{c}Eli Lilly and Company, Indianapolis, IN, USA

\textsuperscript{d}Adelphi Group Products, Macclesfield, Cheshire, UK

\textsuperscript{e}Dermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

\textsuperscript{f}Dermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Corresponding author: Catherine Reed

Email: reed_catherine@lilly.com
Supplementary Table 1. Baseline characteristics of patients completing self-completion form (responders) versus patients not completing these forms (non-responders). Data derived from patient record forms completed by physicians.

| Parameter                  | France        |            |            | Italy         |            |            | UK           |            |
|---------------------------|---------------|------------|------------|---------------|------------|------------|--------------|------------|
|                           | PSC responder | PSC non-responder | PSC responder | PSC non-responder | PSC responder | PSC non-responder |
| Number of patients        | 69            | 244        | 129        | 180           | 64          | 224        |
| Age (years)               | 39.5 (16.4)   | 36.0 (14.5) | 38.1 (14.7) | 38.7 (15.6)   | 37.6 (12.9)  | 37.2 (17.1) |
| Sex (% male)              | 42            | 58*        | 50         | 49            | 53          | 49         |
| Ethnicity (% White)       | 91*           | 79         | 99*        | 91            | 92*         | 74         |
| BMI                       | 24.4 (3.4)    | 23.8 (3.3) | 27.6 (30.4)| 24.7 (3.7)    | 26.5 (4.7)  | 25.9 (4.5) |
| % employed                | 61            | 57         | 49         | 51            | 66*         | 52         |
| Time since diagnosis (years) | 14.5 (15.5)  | 12.5 (12.8)| 9.7** (9.8)| 4.8 (8.3)     | 11.3 (11.7) | 14.7 (13.5)|
| Current BSA affected (%)  | 19.9 (15.0)   | 22.4 (17.8)| 27.6 (15.7)| 23.6 (19.0)   | 24.7 (17.6) | 25.4 (20.4)|
| Current mean EASI score   | 9.6 (1.1)     | 9.4 (0.6)  | 8.3 (0.5)  | 7.9 (0.5)     | 10.6 (1.3)  | 12.0 (0.6) |
| Current EASI severity category (%) |            |            |            |               |             |             |
| Clear (0–1)               | 3             | 4          | 1          | 2             | 2           | 2          |
| Mild (1.1–7)              | 54            | 46         | 50         | 55            | 47          | 35         |
|                      | 30 | 40 | 46 | 39 | 38 | 49 |
|----------------------|----|----|----|----|----|----|
| Moderate (7.1–21)    | 13 | 9  | 3  | 4  | 12 | 14 |
| Severe (21.1–50)     | 0  | 0  | 0  | 0  | 2  | 0  |
| Very severe (50.1–72)|  0 |  0 |  0 |  0 |  2 |  0 |
| Currently flaring (%)| 53 | 54 | 37 | 35 | 38 | 55*|
| Flared in past 12 months (%) | 85 | 71 | 54 | 62 | 94*| 75 |

Current disease status (%)

|                      | 41 | 60*| 64 | 63 | 48 | 39 |
|----------------------|----|----|----|----|----|----|
| Controlled           | 16 | 22 | 22 | 16 | 17 | 24 |
| Improving            | 25 | 38*| 42 | 47 | 31*| 15 |
| Stable               | 59*| 40 | 36 | 36 | 52 | 61 |
| Uncontrolled         | 23 | 14 | 27 | 25 | 41*| 28 |
| Changeable           | 36 | 25 | 10 | 11 | 11 | 34*|
| Deteriorating        | 36 | 25 | 10 | 11 | 11 | 34*|

*Mean values (standard deviation) unless indicated otherwise

*Improving and stable combined

*Changeable and deteriorating combined

BMI = body mass index; BSA = body surface area; EASI = Eczema Area and Severity Index; PSC = patient self-completion form

*p < 0.05 for the difference between PSC responders and PSC non-responders (Fisher’s exact test)

**p < 0.05 for the difference between PSC responders and PSC non-responders (t-test)
Supplementary Table 2. Current conventional systemic therapy by atopic dermatitis severity in France, Italy and the UK. Data derived from patient record forms completed by physicians.

| Conventional systemic therapy | France         | Italy          | UK             |
|-------------------------------|----------------|----------------|----------------|
|                               | Mod/Sev  | Moderate | Severe | Mod/Sev  | Moderate | Severe | Mod/Sev  | Moderate | Severe |
| Number of patients            | 305      | 237      | 68     | 294      | 247      | 47     | 286      | 239      | 47     |
| Cyclosporine                  | 25 (8)   | 13 (5)   | 12 (18) | 36 (12)  | 34 (14)  | 2 (4)  | 17 (6)   | 10 (4)   | 7 (15) |
| Methotrexate                  | 26 (9)   | 16 (7)   | 10 (15) | 23 (8)   | 17 (7)   | 6 (13) | 17 (6)   | 15 (6)   | 2 (4)  |
| Azathioprine                  | 3 (1)    | 2 (1)    | 1 (1)   | 14 (5)   | 14 (6)   | 0 (0)  | 9 (3)    | 6 (3)    | 3 (6)  |
| Mycophenolate mofetil         | 1 (0)    | 0 (0)    | 1 (1)   | 0 (0)    | 0 (0)    | 0 (0)  | 9 (3)    | 9 (4)    | 0 (0)  |
| Any (all combined)            | 55 (18)  | 31 (13)  | 24 (35) | 73 (25)  | 65 (26)  | 8 (17) | 51 (18)  | 39 (16)  | 12 (26)|

Data are presented as N or n (%)

Mod/Sev = moderate or severe